Literature DB >> 6214039

Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.

R A Smith, R J Dupe, P D English, J Green.   

Abstract

A derivative of human lys-plasmin in which the active site has been reversibly acylated (BRL 26920; p-anisoyl human lys-plasmin) has been examined as a fibrinolytic agent in a previously described rabbit model of venous thrombosis and shown to be significantly more active and less fibrinogenolytic than free plasmin. A p-anisoylated derivative of a streptokinase (SK)-activated plasmin preparation was significantly less fibrinogenolytic in vivo than the non-acylated enzyme. Acylation increased the fibrinolytic activity of preparations of SK-plasmin activator complexes. BRL 26921, the active site anisoylated derivative of the primary 2-chain SK-plasminogen complex was the most potent fibrinolytic agent studied. SK-Val442-plasminogen complexes, free or acylated, were biologically inactive in this model and confirm the essential nature of fibrin binding processes for effective thrombolysis in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214039

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  An active-site titrant for human tissue-type plasminogen activator.

Authors:  R A Smith
Journal:  Biochem J       Date:  1986-10-15       Impact factor: 3.857

2.  Non-exchange of streptokinase from anisoylated plasminogen streptokinase activator complex and other acylated streptokinase-plasminogen complexes.

Authors:  R A Smith
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro.

Authors:  R Fears
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex.

Authors:  H Ferres; M Hibbs; R A Smith
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

6.  The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.

Authors:  R Cassels; R Fears; R A Smith
Journal:  Biochem J       Date:  1987-10-15       Impact factor: 3.857

7.  [Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].

Authors:  P Doenecke; H Schwerdt; P Hellstern; E Wenzel; L Bette
Journal:  Klin Wochenschr       Date:  1986-08-01

Review 8.  Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

Authors:  J P Monk; R C Heel
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

9.  The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit.

Authors:  G R May; W Paul; P Crook; K D Butler; C P Page
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.